EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Paradigm Biopharmaceuticals Limited (PBIGF) fair value: what the stock is really worth

As of Oct 1, 2026: fair value of Paradigm Biopharmaceuticals Limited $0.01, price $0.01, upside +9.4%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN AU000000PAR5

PB Paradigm Biopharmaceuticals Limited logo Thin data Oct 1, 2026

Paradigm Biopharmaceuticals Limited

PBIGF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0116 · Fairly valued (+9.4%)
!Quality 37/100
!Weak Growth (revenue 3y −13.0 %/yr)
!negative free cash flow
!Narrow moat 3/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$13.25 $0.0106 Fair Value $0.0116 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range $0.0106 – $13.25 · fair‑value band $0.0116 – $0.0127 · the $0.0106 price screens below the $0.0116 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia.

Show more

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Stock analysis

Paradigm Biopharmaceuticals Limited (PBIGF) currently trades at $0.0106, while our model-based Fair Value estimate is $0.0116, so the stock looks roughly fairly valued today (gap 8.6%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0116 (bear) to $0.0127 (bull), the price of $0.0106 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Paradigm Biopharmaceuticals Limited reported revenue of A$52.1K in FY2025 versus A$20.6K in FY2021, a compound +26.2%/yr. Reported net income was −A$18.8M in FY2025.

Key figures

Market cap $103M · EPS (TTM) $−0.0700 · Return on equity −180% · Return on assets (EBIT) −111% · Operating margin −86,794% · Revenue growth (YoY) +50.6% · Free cash flow −A$16.0M · Net cash A$16.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 97% below its 52-week high and 657% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 9%, PBIGF screens richer than that median.

Fair Value models

Bear $0.0116 Fair Value $0.0116 Bull $0.0127
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0100 $0.0200 $0.0300 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0100 $0.0200 $0.0300 50

Open the full fair value analysis →

Notify me when PBIGF reaches fair value

Put PBIGF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 40 · Market factors (momentum, volatility) 20

Profitability 0
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 97
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 4
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−20.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−293.1% (2019) → −43,910.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch PBIGF, get fair value alerts →

Compare Paradigm Biopharmaceuticals Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Paradigm Biopharmaceuticals Limited · Fair Value
$0.0116 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Paradigm Biopharmaceuticals Limited Fair Value". https://www.fairvalue-calculator.com/stock/PBIGF

Frequently asked questions

Is Paradigm Biopharmaceuticals Limited (PBIGF) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of $0.0116 versus a price of $0.0106, about +9% upside (fairly valued).
What is the fair value of PBIGF?
Our model-based fair value for Paradigm Biopharmaceuticals Limited is $0.0116 (as of Oct 1, 2026), built from audited fundamentals. The current price: $0.0106.
What is the quality score of PBIGF?
Paradigm Biopharmaceuticals Limited has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Paradigm Biopharmaceuticals Limited (PBIGF)?
Our model-based price target is the fair value of $0.0116 (as of Oct 1, 2026) from 1 valuation models. Cautious scenario $0.0116, optimistic scenario $0.0127. It is a calculation from audited fundamentals, not an analyst target.
What is the Paradigm Biopharmaceuticals Limited stock forecast for 2026?
Our models put fair value at $0.0116, about +9% upside versus a price of $0.0106 (fairly valued). Cautious scenario $0.0116, optimistic scenario $0.0127. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Paradigm Biopharmaceuticals Limited (PBIGF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Paradigm Biopharmaceuticals Limited it is $0.0116 per share (as of Oct 1, 2026), against a price of $0.0106. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Paradigm Biopharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, PBIGF trades below its calculated fair value: price $0.0106, fair value $0.0116, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PBIGF?
No. The price is what the market pays today ($0.0106); the fair value is what the company's own numbers justify ($0.0116). For Paradigm Biopharmaceuticals Limited the two are $0.0010 per share apart. That gap is exactly why we show both numbers side by side.
How much is Paradigm Biopharmaceuticals Limited worth?
The market values Paradigm Biopharmaceuticals Limited at about $103M (market capitalisation, as of Oct 1, 2026). Per share that is $0.0106; our models calculate a fair value of $0.0116 per share.
What do the bullish and bearish scenarios say about PBIGF?
Our models span a range for Paradigm Biopharmaceuticals Limited: cautious scenario $0.0116, base $0.0116, optimistic $0.0127 per share (as of Oct 1, 2026, price $0.0106). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is PBIGF from its 52-week high?
Paradigm Biopharmaceuticals Limited trades at $0.0106, about 97% below its 52-week high of $0.3468 and 657% above the low of $0.0014 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0116 is for.
Which stocks are comparable to Paradigm Biopharmaceuticals Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Paradigm Biopharmaceuticals Limited stock attractive at the current price?
The data as of Oct 1, 2026: price $0.0106, calculated fair value $0.0116 (+9%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PBIGF calculated?
We run Paradigm Biopharmaceuticals Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0116, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Paradigm Biopharmaceuticals Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Paradigm Biopharmaceuticals Limited (PBIGF)?
The closing price on Oct 1, 2026 was $0.0106. Our model-based fair value is $0.0116, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Paradigm Biopharmaceuticals Limited right now?
The price is below even our cautious bear case ($0.0116). The market is more pessimistic than our downside scenario. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0116 to $0.0127), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Paradigm Biopharmaceuticals Limited

How large is the market capitalisation of Paradigm Biopharmaceuticals Limited (PBIGF)?
The market capitalisation of Paradigm Biopharmaceuticals Limited is $103M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Paradigm Biopharmaceuticals Limited (PBIGF)?
Earnings per share at Paradigm Biopharmaceuticals Limited are $−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Paradigm Biopharmaceuticals Limited (PBIGF)?
The return on equity (ROE) of Paradigm Biopharmaceuticals Limited is −180% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Paradigm Biopharmaceuticals Limited (PBIGF)?
On an EBIT basis the return on assets of Paradigm Biopharmaceuticals Limited is −111% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Paradigm Biopharmaceuticals Limited (PBIGF)?
The operating margin of Paradigm Biopharmaceuticals Limited is −86,794% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Paradigm Biopharmaceuticals Limited (PBIGF)?
Revenue at Paradigm Biopharmaceuticals Limited is growing +50.6% versus a year earlier (3y avg −13.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Paradigm Biopharmaceuticals Limited (PBIGF) generate?
The free cash flow of Paradigm Biopharmaceuticals Limited is −A$16.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Paradigm Biopharmaceuticals Limited (PBIGF) hold?
Paradigm Biopharmaceuticals Limited holds more cash than debt, A$16.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.